Plain-English translation of NCT03567889 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called that is injected directly into melanoma tumors before surgery. The study compares two groups: one that receives injections followed by surgery and standard follow-up treatments, and another that goes directly to surgery and standard treatments. Researchers want to see if the medication helps prevent melanoma from coming back.
Advanced melanoma (stage IIIB, IIIC, or IIID) is serious and often returns after surgery, even with standard treatments. This trial is testing whether giving this medication before surgery might help keep the cancer from coming back.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups. One group will receive injections into the melanoma lesions over 4 weeks, then have surgery within 4 weeks after that, followed by standard follow-up treatments. The other group will go directly to surgery within 4 weeks, then receive standard follow-up treatments. Both groups will be monitored for up to 6 years to track whether the melanoma returns and how long patients survive.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States